Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVER4010001 plus Pembrolizumab in Advanced Solid Tumors
NCT04699643Phase 2Unknown
- Sponsor
- EverNov Medicines
- Start
- Jul 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roblitinib in solid tumor (advanced stage), sponsored by EverNov Medicines. Status: unknown.
02
Drugs
roblitinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04699643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699643.